SEARCH

SEARCH BY CITATION

References

  • 1
    Ginzler EM, Diamond HS, Weiner M, Schlesinger M, Fries JF, Wasner C, Medsger TA Jr, Ziegler G, Klippel JH, Hadler NM, Albert DA, Hess EV, Spencer-Green G, Grayzel A, Worth D, Hahn BH, Barnett EV: A multicenter study of outcome in systemic lupus erythematosus. I. Entry variables as predictors of prognosis. Arthritis Rheum 25: 601611, 1982
  • 2
    Schur PH, Sandson J: Immunologic factors and clinical activity in systemic lupus erythematosus. N Engl J Med 278: 533538, 1968
  • 3
    Lange K, Wasserman E, Slobody LB: Significance of serum complement levels for diagnosis and prognosis of acute and subacute glomerulonephritis and lupus erythematosus disseminatus. Ann Intern Med 53: 636646, 1960
  • 4
    Webster R, Hong S, Johnston R, Henson P: Biological effects of human complement fragments C5a and C5a desArg on neutrophil function. Immunopharmacology 2: 201219, 1980
  • 5
    Buyon JP, Shaddick N, Berkman R, Hopkins P, Dalton J, Weissmann G, Winchester R, Abramson S: Surface expression of CR3 on neutrophils (PMN) as a marker of disease activity in systemic lupus erythematosus (SLE). Clin Immunol Immunopathol 46: 141149, 1988
  • 6
    Belmont HM, Hopkins P, Edelson HS, Kaplan HB, Ludewig R, Weissmann G, Abramson SB: Complement activation during systemic lupus erythematosus: C3a and C5a anaphylatoxins circulate during exacerbations of disease. Arthritis Rheum 29: 10851089, 1986
  • 7
    Hopkins P, Belmont HM, Buyon J, Philips M, Weissmann G, Abramson SB: Increased levels of plasma anaphylatoxins in systemic lupus erythematosus predict flares of the disease and may elicit vascular injury in lupus cerebritis. Arthritis Rheum 31: 632641, 1988
  • 8
    Gawryl MS, Chudwin DS, Langlois PF, Lint TF: The terminal complement complex, C5b-9, a marker of disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 31: 188195, 1988
  • 9
    Falk RJ, Dalmasso AP, Kim Y, Lam S, Michael A: Radioimmunoassay of the attack complex of complement in serum from patients with systemic lupus erythematosus. N Engl J Med 312: 15941599, 1985
  • 10
    Kerr LD, Adelsberg BR, Schulman P, Spiera H: Factor B activation products in patients with systemic lupus erythematosus: a marker of severe disease activity. Arthritis Rheum 32: 14061413, 1989
  • 11
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25: 12711277, 1982
  • 12
    Buyon JP, Tamerius J, Ordorica S, Young B, Abramson SB: Activation of the alternative complement pathway accompanies disease flares in systemic lupus erythematosus during pregnancy. Arthritis Rheum 35: 5561, 1992
  • 13
    Kolb WP, Morrow PR, Tamerius JD: Ba and Bb fragments of factor B activation: fragment production, biological activities, neoepitope expression and quantitation in clinical samples. Complement Inflamm 6: 175204, 1989
  • 14
    Kolb WP, Latham AL, Morrow PR, Tamerius JD: EIA quantitation of C4d fragment levels in patient samples using a monoclonal antibody to a C4d fragment neoantigenic determinant. Complement Inflamm 5: 214, 1988
  • 15
    Kolb WP, Morrow PR, Jensen FC, Tamerius JD: Development of a highly sensitive capture EIA for the quantitation of the SC5b-9 complex in human plasma using a monoclonal antibody reactive with a poly C9 neoantigenic determinant. Complement Inflamm 5: 213214, 1988
  • 16
    Aranout MA, Hakim RM, Todd RF, Dana N, Colten HR: Increased expression of an adhesion-promoting surface glycoprotein in the granulocytopenia of hemodialysis. N Engl J Med 312: 457462, 1985
  • 17
    Frank MM, Hamburger MI, Lawley TJ, Kimberly RP, Plotz PH: Defective reticuloendothelial system Fc-receptor function in systemic lupus erythematosus. N Engl J Med 300: 518523, 1979
  • 18
    Kimberly RP, Parris TM, Inman RD, McDougall JS: Dynamics of mononuclear phagocyte system Fc receptor function in systemic lupus erythematosus: relation to disease activity and circulating immune complexes. Clin Exp Immunol 51: 261268, 1983
  • 19
    Conrad DH, Carlo JR, Ruddy S: Interaction of βIH-globulin with cell-bound C3b: quantitative analysis of binding and influence of alternative pathway components on binding. J Exp Med 147: 17921805, 1978
  • 20
    Fearon DT: Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte and monocyte. J Exp Med 152: 2030, 1980
  • 21
    Kinoshita T, Medoff ME, Silber R, Nussenzweig V: Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria. J Exp Med 162: 7592, 1985
  • 22
    Wilson JG, Ratnoff WD, Schur PH, Fearon DT: Decreased expression of the C3b/C4b receptor (CR1) and the C3d receptor (CR2) on B lymphocytes and of CR1 on neutrophils of patients with systemic lupus erythematosus. Arthritis Rheum 29: 739747, 1986
  • 23
    Smith CA, Vogel CW, Mueller-Eberhard HJ: Ultrastructure of cobra venom factor dependent C3-C5 convertase and its zymogen, factor B, of human complement. J Biol Chem 257: 98799882, 1982
  • 24
    Petri M, Genovese M, Engle E, Hochberg M: Definition, incidence, and clinical description of flare in systemic lupus erythematosus: a prospective cohort study. Arthritis Rheum 34: 937944, 1991
  • 25
    Liang MH, Socher SA, Larson MG, Schur PH: Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 32: 11071118, 1989
  • 26
    Moore FD Jr, Davis C, Rodrick M, Mannick JA, Fearon DT: Neutrophil activation in thermal injury as assessed by increased expression of complement receptors. N Engl J Med 314: 948953, 1986
  • 27
    Abramson SB, Dobro J, Eberle MA, Benton M, Reibman J, Epstein H, Rapoport DM, Belmont HM, Goldring RM: Acute reversible hyposemia in systemic lupus erythematosus. Ann Intern Med 114: 941947, 1991
  • 28
    Perez HD, Hooper C, Volanakis J, Ueda A: Specific inhibitor of complement (C5)-derived chemotactic activity in systemic lupus erythematosus related antigenically to the Bb fragment of human factor B. J Immunol 139: 484489, 1987